|
Medivir is endeavoring to attain sustainable profitability from:
- Revenues from current and future licensing agreements on its preclinical and clinical pharmaceutical development projects.
- Revenues from regional sales, primarily of specialist pharmaceuticals. These may be proprietary products either developed in-house, received as remuneration in licensing agreements or acquired, as well as the co-promotion of products belonging to other companies.
- Revenues from proprietary projects that Medivir brings to market registration.
|
